These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22085389)

  • 21. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild renal impairment and the efficacy and safety of liraglutide.
    Davidson JA; Brett J; Falahati A; Scott D
    Endocr Pract; 2011; 17(3):345-55. PubMed ID: 21700561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R; Davies MJ
    Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of the therapeutic uses of liraglutide.
    Ryan GJ; Foster KT; Jobe LJ
    Clin Ther; 2011 Jul; 33(7):793-811. PubMed ID: 21741090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide.
    Drucker DJ; Dritselis A; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Apr; 9(4):267-8. PubMed ID: 20357801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide for type 2 diabetes mellitus.
    Kela R; Khunti K; Davies MJ
    Expert Opin Biol Ther; 2011 Jul; 11(7):951-9. PubMed ID: 21563859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early clinical studies with liraglutide.
    Schmidt WE
    Int J Clin Pract Suppl; 2010 Oct; (167):12-20. PubMed ID: 20887300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.